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1 ABSTRACT 
 
BACKGROUND 
Schizophrenia is a disabling mental disorder. It affects as much as 1% of the 
population worldwide. A proportion of one fifth to one third of patients with 
schizophrenia derive little or no benefit from treatment with first or second 
generation antipsychotics. In these treatment refractory patients, clozapine has 
been shown to be the treatment of choice. Unfortunately, however, approximately 
one third of treatment-refractory patients have persistent positive symptoms. The 
need to provide real-world suggestions for patients who do not have an optimal 
response to clozapine has prompted European and American treatment guidelines 
to recommend the concurrent prescription of a second antipsychotic in addition to 
clozapine in partially responsive patients, with no indication on which agent 
should be prescribed. 
OBJECTIVE 
The main clinical question to be answered by CHAT is the relative efficacy and 
tolerability of combination treatment with clozapine plus aripiprazole compared to 
combination treatment with clozapine plus haloperidol in patients with an 
incomplete response to treatment with clozapine over an appropriate period of 
time. 
METHODS  
The Clozapine Haloperidol Aripiprazole Trial (CHAT) is a prospective, 
multicentre, pragmatic, randomized, parallel group, superiority trial. Patients were 
assessed at baseline and after three, six and 12 months of follow-up. During the 
study, patients and clinicians were not blind to pharmacological treatments 
provided during the trial. However, outcome assessments based on rating scales 
2 
 
were performed by trained assessors masked to the allocated treatment. CHAT 
was undertaken in compliance with Good Clinical Practice guidelines and the 
Declaration of Helsinki. The study protocol was approved by Italian Medicine 
Agency (Agenzia Italiana del Farmaco) and received ethical approval in each 
participating site. All phases of CHAT were recorded following the Consolidated 
Standard of Reporting of Trials (CONSORT) statement. 
RESULTS 
106 patients were enrolled in the study and randomly assigned to treatment. After 
three months (13.2 vs 15.1%, p = 0.780), as well as after twelve months (30.8 vs 
38.0%, p = 0.442), the analysis of the primary outcome revealed no difference in 
the proportion of patients who discontinued treatment between the aripiprazole 
and haloperidol groups. 
CONCLUSIONS 
This study indicates that augmentation of clozapine with aripiprazole offers no 
benefit with regard to treatment withdrawal and overall symptoms in 
schizophrenia as compared with augmentation with haloperidol. The analysis of 
the 12-month data from CHAT, confirm a trend of favourable advantage in the 
perception of adverse effects with aripiprazole, found out at 3-month analysis. 
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2 BACKGROUND 
 
Schizophrenia is a mental disorder characterized by a disintegration of the process 
of thinking and of emotional responsiveness. It most commonly manifests as 
auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and 
thinking, and it is accompanied by significant social or occupational dysfunction. 
As a result of the many possible combinations of symptoms, there is debate about 
whether the diagnosis represents a single disorder or a number of discrete 
syndromes. Despite the etymology of the term from the Greek roots skhizein 
(σχίζειν, "to split") and phrēn, phren- (φρήν, φρεν-; "mind"), schizophrenia does 
not imply a "split mind" and it is not the same as dissociative identity disorder, 
also known as "multiple personality disorder" or "split personality", a condition 
with which it is often confused in public perception (Picchioni and Murray, 2007).  
The original name for this illness, ―dementia praecox,‖ was coined by Emil 
Kraepelin, a German psychiatrist in the late nineteenth and early twentieth 
century, whose description of the illness remains a guiding force for modern 
investigators.  
 Schizophrenia is a relatively common illness and it is certainly the most 
common form of psychotic disorder. The mean incidence of schizophrenia 
reported in epidemiological studies, when the diagnosis is limited to core criteria 
and corrected for age, is 0.11 per 1000 (range 0.07–0.17 per 1000); if broader 
criteria are used, this figure doubles to 0.24 per 1000 (range 0.07–0.52 per 1000) 
(Broome et al.  2005; Jablensky et al.  1992). 
Average rates for men and women are similar, although the mean age of onset is 
about 5 years greater in women (hence a lower female rate in adolescence), with a 
second smaller peak after the menopause. Although most patients fall ill in late 
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teenage or early adult years, the range of age of onset is wide: childhood onset 
may occur, and in some instances symptoms may not appear until the sixties. 
The lifetime prevalence of schizophrenia is between 0.4 and 1.4% (Cannon and 
Jones, 1996). The National Survey of Psychiatric Morbidity in the UK found a 
population prevalence of probable psychotic disorder of 5 per 1000 in the age 
group 16 to 74 years (Singleton, 2000). 
 There may or may not be a prodrome before the actual onset of symptoms. 
In some cases the ―pre-morbid personality‖ appears completely normal. In others, 
however, peculiarities may have been apparent for years or even decades before 
the onset. In cases where the prodrome began in childhood, the history may reveal 
introversion and peculiar interests. In cases where the prodrome began later, after 
the patient‘s personality was formed, family members may recall a stretch of time 
wherein the patient ―changed‖ and was no longer ―the same.‖ Prior interests and 
habits may have been abandoned and replaced by a certain irritable seclusiveness, 
or perhaps suspiciousness. 
The onset of symptoms per se may be acute or insidious. Acute onsets tend to 
span a matter of weeks or months and may be characterized by confusion or at 
times by depressive symptoms. Patients may recognize that something is wrong, 
and they may make some desperate attempts to bring some order into the 
fragmenting experience of life. By contrast, in cases with an insidious onset the 
patient may not be particularly troubled at all. Over many months or a year or 
more, evanescent changes may occur: fleeting whispers, vague intimations, or 
strange occurrences. 
 The possible causes of schizophrenia are not well understood. Genetics, 
early environment, neurobiology, psychological and social processes appear to be 
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important contributory factors; some recreational and prescription drugs appear to 
cause or worsen symptoms.  
Current psychiatric research is focused on the role of neurobiology, but this 
inquiry has not isolated a single organic cause.  
The evidence does not point to any single cause. Increasingly, it is thought that 
schizophrenia and related psychoses result instead from a complex interaction of 
multiple factors (Broome et al.  2005; Garety et al.  2007). 
Much of the research evidence on the aetiology of schizophrenia is consistent with 
the long-standing ‗vulnerability stress‘ model (Nuechterlein and Dawson, 1984). 
This paradigm suggests that individuals possess different levels of vulnerability to 
schizophrenia, which are determined by a combination of biological, social and 
psychological factors. It is proposed that vulnerability results in the development 
of problems only when environmental stressors are present. If there is great 
vulnerability, relatively low levels of stress might be sufficient to cause problems. 
If there is less vulnerability, problems develop only with higher levels of stress. 
The model is consistent with a wide variety of putative causes of the disorder, as 
well as the differential relapse and readmission rates observed among people with 
schizophrenia. Recent research has therefore attempted to specify more precisely 
the nature of any vulnerability and of types of environmental stress. This includes 
biological hypotheses about brain biochemistry and pathology (Broome et al.  
2005), and attempts to identify genes that confer susceptibility (Craddock et al.  
2005). Biochemical theories have centred mainly on the ‗dopamine hypothesis‘, 
for which there is enduring support (Kapur, 2003). This argues that schizophrenia 
might be related to problems in the regulation of the neurotransmitter dopamine in 
the prefrontal cortex.  
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Psychological factors can be divided into problems with basic cognitive functions, 
such as learning, attention, memory or planning, and biases in emotional and 
reasoning processes. problems in cognitive function are related to research in 
brain structure and function, while emotional processes may be linked to social 
factors. Studies of psychological factors thus provide a bridge between biological 
and social theories. Both types of psychological factor have been implicated in the 
development of symptoms of schizophrenia (Garety et al.  2001; Garety et al.  
2007; Gray, 2011; Green, 1992; Hemsley, 1993).  
Recently, depression and anxiety, which were previously considered unimportant 
by researchers, have been found to contribute to the symptoms of schizophrenia 
(Birchwood, 2003; Freeman and Garety, 2003; Krabbendam and van, 2005).  
Estimates of the heritability of schizophrenia tend to vary owing to the difficulty 
of separating the effects of genetics and the environment although twin and 
adoption studies have suggested a high level of heritability. It has been suggested 
that schizophrenia is a condition of complex inheritance, with many different 
potential genes each of small effect, with different pathways for different 
individuals. At the same time, different social causes have been under light.  
Recently there has been a resurgence of interest in investigating social and 
environmental factors. Living in an urban environment has been consistently 
found to be a risk factor for schizophrenia (Crow, 2008; O'Donovan et al.  2009). 
Social disadvantage has been found to be a risk factor, including poverty (Crow, 
2008) and migration related to social adversity, racial discrimination, family 
dysfunction, unemployment or poor housing conditions (Selten et al.  2007). 
Childhood experiences of abuse or trauma have also been implicated as risk 
factors for a diagnosis of schizophrenia later in life (Janssen et al.  2004; 
MacMillan et al.  2001).  
7 
 
Parenting is not held responsible for schizophrenia but unsupportive dysfunctional 
relationships may contribute to an increased risk (Crow, 2008; Selten and Cantor-
Graae, 2005). 
There is now consistent evidence that migrant populations experience raised rates 
and especially  
High rates have been found among certain minority ethnic groups (Cantor-Graae 
and Selten, 2005; Kirkbride et al.  2006). It is thought that this is most likely 
related to the high rates of social adversity and family disruption experienced by 
some migrant populations (Fearon et al.  2006; Selten and Cantor-Graae, 2005). 
In a recent study of people with schizophrenia and a substance abuse disorder, 
over a ten year period, "substantial proportions were above cut-offs selected by 
dual diagnosis clients as indicators of recovery." (Gregg et al.  2007).  
Although about half of all patients with schizophrenia use drugs or alcohol, and 
the vast majority use tobacco, a clear causal connection between drug use and 
schizophrenia has been difficult to prove. The two most often used explanations 
for this are "substance use causes schizophrenia" and "substance use is a 
consequence of schizophrenia", and they both may be correct (McLaren et al.  
2010). 
 Schizophrenia is often described in terms of positive and negative (or 
deficit) symptoms (Sims A., 2002).  
 The term positive symptoms refers to symptoms that most individuals do 
not normally experience but are present in schizophrenia. 
They include: 
 Hallucinations: patients may hear things, often voices, or they may see 
things; hallucination of taste, touch, and smell may also occur. However, of all 
these, the hearing of voices is most characteristic of schizophrenia. 
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The voices may come from anywhere. They come from the air, from the television 
or radio, sometimes they are in clothing, often they are localized to certain parts of 
the body (they come from the bowels, the liver, from ―just behind the ear.‖). They 
may be male or female; the patient may or may not be able to recognize the 
identity of the speaker. Most often, though, the voices are not recognized as 
belonging to anyone; they are from strangers. They may be clear and easily 
understood; sometimes they are deafening and compelling—―everything else is 
shut out.‖ At other times they may be soft, ―just a mumbling,‖ indistinct and 
fading. What the voices say is extremely varied: however, certain themes are 
relatively common. Voices may comment on what the patient is doing. Often two 
voices argue with one another about the patient. Often the voice echoes or repeats 
what the patient thought. Thoughts are ―audible‖; they are ―heard out loud‖; they 
are repeated on the television. 
At times ―command hallucinations,‖ or voices that tell the patient what to do, may 
be heard. At times these are imperious and irresistible; at other times they are soft, 
―suggestive‖ only. Sometimes they command innocuous things; the patient may 
be directed to shave again. At other times they may command the patient to 
commit suicide or to hurt others. Usually the commands can be resisted, but not 
always. Sometimes they are overwhelmingly compelling—―they must be 
obeyed.‖ The patients generally hear only short phrases, perhaps single words. 
Only very rarely do the voices speak at length in a coherent way. Often the patient 
is tortured by the voices. 
Rarely patients are encouraged or comforted by the voices. Most patients find the 
voices as real sounding as the voice of any other person. They may talk back to 
them out loud or may even argue with them.  
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Visual hallucinations, though common, play a relatively less prominent part in the 
clinical picture of schizophrenia than do auditory hallucinations. They may be 
poorly formed, indistinct, seen only ―out of the corner of the eye.‖ They may, 
however, be vivid and compellingly realistic. Strange people walk the halls; the 
devil in violent red appears in front of the patient; heads float through the air. 
Reptilian forms appear in the bath; things crawl in the food; a myriad of insects 
appear in the bedding. 
Hallucinations of smell and taste, though not common, may be particularly 
compelling to the patient. Tastes, often foul and bitter, may appear on the tongue 
―from nowhere.‖ Often, however, something is detected in food or drink. Patients 
may refuse all food and drink and declare that they have had enough poison 
already. 
Hallucinations of touch, also known as haptic or tactile hallucinations, are 
relatively common. Something is crawling on them; a pricking is coming from 
behind. At night all manner of things are felt. Fluids are poured over the body; a 
caressing is felt, as are lips on all parts. Electrical sensations may be felt at any 
time. Sometimes patients may feel things inside their bodies.  
 Delusions: they are almost universal in schizophrenia. The content of the 
delusions is extremely varied: patients may feel persecuted; they may have 
grandiose ideas; all manner of things may refer and pertain to them; thoughts may 
be broadcast, withdrawn, or inserted into them; they may feel influenced and 
controlled by outside forces; bizarre, loathsome events may occur. These beliefs 
may grow in the patient slowly. At first there may be only an inkling, a suspicion; 
only with time does conviction occur. Conversely, sudden enlightenment may 
occur; all may be immediately clear. Sometimes patients may have lingering 
doubts about the truth of these beliefs, but for most they are as self-evident as any 
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other belief. Occasionally patients may argue with those who disagree, but for the 
most part they do not press their case on the unbeliever. Most often the delusions 
are poorly coordinated with each other; typically they are contradictory and poorly 
elaborated. Occasionally, however, they may be systematized, and this is 
especially the case in the paranoid subtype. 
Delusions of persecution are particularly common. 
Grandiose delusions also occur frequently, often in conjugation with delusions of 
persecution. 
Commonly most patients do not act on their delusions; rather they seem content to 
be comforted and sustained by them. Exceptions do occur, of course. 
Delusions of reference are intimately tied to delusions of persecution or of 
grandeur. Here patients believe that otherwise chance occurrences or random 
encounters have special meaning for them. What was done refers to them; it 
pertains to them. There are no more coincidences in life, no accidental 
happenings. To the grandiose patient the events of creation are exalting; to the 
persecuted patient, walking the streets can provoke a terrifying self-consciousness. 
Everything is pregnant with meaning. Some patients may develop some peculiarly 
bizarre beliefs about thinking itself, known as thought broadcasting, thought 
withdrawal, and thought insertion. In thought broadcasting patients experience 
thoughts as being broadcast from their heads, as if by electricity. In thought 
withdrawal the patients‘ thoughts are removed, taken from them. The mind is left 
blank. Patients who experience this symptom of thought withdrawal may 
concurrently, if they happen to be speaking their thoughts, display the sign known 
as ―thought blocking.‖ Here, patients in the middle of speaking abruptly cease 
talking, and this happens precisely because they abruptly find themselves with no 
thoughts to express. In thought insertion, a phenomenon opposite to that of 
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thought withdrawal occurs. Here patients experienced the insertion of thoughts 
into their minds. The thoughts are alien, not their own; they were placed there by 
some other agency.  
Another delusion is the delusion of doubles, also known as the ―Capgras 
phenomenon,‖ or the delusion of impostors. Here the patient believes that 
someone, or something, has occupied the body of another. Although the body 
looks the same and the voice is the same, indeed, for all intents and purposes, it is 
the same person, yet the patient knows without doubt that it is an impostor.  
 Disorganized speech: this ―formal thought disorder‖ is most often 
characterized as ―loosening of associations‖; less frequently it is referred to as 
incoherence or ―derailment.‖ The patient‘s speech becomes illogical; ideas are 
juxtaposed that have no conceivable connection. At its extreme, loosening of 
associations may present as a veritable ―word salad.‖ Here any inner connection 
among the various ideas and concepts is lost; it is as if they come at random. The 
thoughts are no longer ―goal-directed‖; they no longer cohere in pursuit of a 
common purpose. Patients seem little concerned about their incoherence. 
Allied to loosening of associations are neologisms. These are words that occur in 
the normal course of the patient‘s speech and that the patient treats as an integral 
part of it, but that convey no more meaning to the listener than if they were from a 
long-dead foreign language. To the patient, however, they have as much meaning 
and status as any other word, but that meaning is private and inaccessible to the 
listener.  
 
 Negative symptoms are things that are not present in schizophrenic persons 
but are normally found in healthy persons, that is, symptoms that reflect the loss 
or absence of normal traits or abilities.  
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Common negative symptoms include: 
 Flatted or blunted affect and emotion: lifeless and wooden facial expression 
accompanied by an absence or diminution of all feelings. 
This is quite different from a depressed appearance. In depression patients appear 
drained or weighted down; there is a definite sense of something there. In 
flattening, however, patients seem to have nothing to express; they are simply 
devoid of emotion. They appear unmoved, wooden, and almost at times as if they 
were machines. 
 Alogia : poverty of speech. 
It is said to occur when patients, though perhaps talking a normal amount, seem to 
―say‖ very little. There is a dearth of meaningful content to what they say and 
speech is often composed of stock phrases and repetitions. 
 Poverty of thought: far-reaching impoverishment of the entire thinking of 
the patient. 
The patient may complain of having ―no thoughts,‖ that ―the head is empty,‖ that 
there are no ―stirrings.‖ Of its own accord nothing ―comes to mind.‖ If pressed by 
a question the patient may offer a sparse reply, then fail to say anything else. 
 Avolition: lack of motivation. 
It is referred to by Kraepelin as ―annihilation of the will,‖ is said to be present 
when patients have lost the capacity to embark on almost any goal-directed 
activity. 
 Anhedonia: inability to experience pleasure. 
 Asociality: lack of desire to form relationships.  
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Research suggests that negative symptoms contribute more to poor quality of life, 
functional disability, and the burden on others than do positive symptoms 
(Velligan DI and Alphs LD., 2008).  
 
 In one uncommon subtype, the person manifest signs of catatonia. 
Catatonic symptoms include negativism, catalepsy, posturing, stereotypies and 
echolalia or echopraxia: 
 Negativism: mulish, automatic, almost instinctual opposition to any course 
of action suggested, demanded, or merely expected.  
 Catalepsy: waxy flexibility. 
It is characterized by a state of continual and most unusual muscular tension. 
 Posturing: the patient, for no discernible reason, assumes and maintains a 
bizarre posture. One may keep the arms cocked; another stood bent at the waist to 
the side. 
 Stereotypies: bizarre, perseverated behaviours. 
A patient, for example, may march back and forth along the same line for hours; 
another may repeatedly dress and undress. Most patients can offer no reason for 
their senseless activity.  
 Echolalia and echopraxia: patient‘s behaviour mirrors that of the other 
person, and, importantly, when this happens automatically, and in the absence of 
any request. 
 
 Diagnosis of schizophrenia is based on the self-reported experiences of the 
person, and abnormalities in behaviour reported by family members, friends or co-
workers, followed by a clinical assessment by a psychiatrist, social worker, 
clinical psychologist, mental health nurse or other mental health professional. 
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The most widely used standardized criteria for diagnosing schizophrenia come 
from the American Psychiatric Association's Diagnostic and Statistical Manual of 
Mental Disorders, version DSM-IV-TR, and the World Health Organization's 
International Statistical Classification of Diseases and Related Health Problems, 
the ICD-10. The latter criteria are typically used in European countries, while the 
DSM criteria are used in the United States and the rest of the world, as well as 
prevailing in research studies. The ICD-10 criteria put more emphasis on 
Schneiderian first-rank symptoms, although, in practice, agreement between the 
two systems is high (Kneisl C.and Trigoboff E, 2009).  
 According to the revised fourth edition of the Diagnostic and Statistical 
Manual of Mental Disorders (DSM-IV-TR), to be diagnosed with schizophrenia, 
three diagnostic criteria must be met (American Psychiatric Association.Task 
Force on DSM-IV.(2000)., 2000):  
1. Characteristic symptoms.  
Two or more of the following, each present for much of the time during a one-
month period (or less, if symptoms remitted with treatment).  
 Delusions 
 Hallucinations 
 Disorganized speech, which is a manifestation of formal thought disorder 
 Grossly disorganized behaviour (e.g. dressing inappropriately, crying 
frequently) or catatonic behaviour 
 Negative symptoms: blunted affect (lack or decline in emotional response), 
alogia (lack or decline in speech), or avolition (lack or decline in motivation) 
If the delusions are judged to be bizarre, or hallucinations consist of hearing one 
voice participating in a running commentary of the patient's actions or of hearing 
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two or more voices conversing with each other, only that symptom is required 
above. 
The speech disorganization criterion is only met if it is severe enough to 
substantially impair communication. 
2. Social/occupational dysfunction. 
For a significant portion of the time since the onset of the disturbance, one or 
more major areas of functioning such as work, interpersonal relations, or self-care, 
are markedly below the level achieved prior to the onset. 
3. Duration. 
Continuous signs of the disturbance persist for at least six months. This six-month 
period must include at least one month of symptoms (or less, if symptoms 
remitted with treatment). 
 
 The DSM-IV-TR contains five sub-classifications of schizophrenia. 
Subtypes of schizophrenia are characterized by particular constellations of 
symptoms and include the following: paranoid, catatonic, hebephrenic (or 
―disorganized‖), simple (which has also been referred to as ―simple deteriorative 
disorder‖), and residual subtype. 
Patients whose illness does not fall into any of these subtypes are said to have an 
―undifferentiated‖ subtype. 
The different subtypes may have different prognoses. Furthermore, knowing the 
subtype allows one to predict with better confidence how any given patient might 
react in any specific situation. 
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Paranoid schizophrenia 
It tends to have a later onset than the other subtypes and, it is characterized 
primarily by hallucinations and delusions. The delusions are generally persecutory 
and referential. In paranoid schizophrenia, more than in the other subtypes, the 
delusions may be somewhat systematized, even plausible. In most cases, however, 
inconsistencies appear, which, however, have no impact on the patients. Often, 
along with persecutory delusions, one may also see some grandiose delusions. 
Rarely, grandiose delusions may be more prominent than persecutory ones and 
may dominate the entire clinical picture. 
 
Catatonic schizophrenia 
It manifests in one of two forms: stuporous catatonia or excited catatonia. 
In the stuporous form one sees varying combinations of immobility, negativism, 
mutism, posturing, and waxy flexibility.  
In the excited form of catatonia one may see purposeless, senseless, frenzied 
activity, multiple stereotypies, and at times extreme impulsivity. Typically, 
despite their extreme activity, these patients remain for the most part withdrawn.  
Rarely Stauder‘s lethal catatonia may occur. Here, as the excitation mounts over 
days or weeks, autonomic changes occur with hyperpyrexia, followed by coma 
and cardiovascular collapse. Although some patients with catatonic schizophrenia 
may display only one of these two forms, in most cases they are seen to alternate 
in the same patient. In some cases a form may last days, weeks, or longer, before 
passing through to the other. In other cases, however, a rapid and unpredictable 
oscillation from one form to another may occur.  
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Hebephrenic (disorganised) schizophrenia 
It tends to have an earlier onset than the other subtypes and tends to develop very 
insidiously. Although delusions and hallucinations are present, they are relatively 
minor, and the clinical picture is dominated by bizarre behaviour, loosened 
associations, and bizarre and inappropriate affect. 
 
Residual schizophrenia 
In this subtype positive symptoms are present at a low intensity only. 
 
Simple schizophrenia  
Insidious and progressive development of prominent negative symptoms with no 
history of psychotic episodes. It has perhaps the earliest age of onset, often first 
beginning in childhood, and shows very gradual and insidious progression over 
many years. Delusions, hallucinations, and loosening of associations are sparse, 
and indeed are for the most part absent. Rather the clinical picture is dominated by 
the annihilation of the will, impoverishment of thought, and flattening of affect. 
Gradually over the years these patients fall away from their former goals and often 
become cold and distant with their former acquaintances. Occasionally some 
bizarre behaviour or a fragmentary delusion may be observed. For the most part, 
however, these patients do little to attract any attention. 
 
Undifferentiated schizophrenia 
It is said to be present when the clinical picture of any individual case does not fit 
well into one of the foregoing subtypes. 
This is not uncommonly the case, and it also appears that in some instances the 
clinical picture, which initially did ―fit‖ a subtype description, may gradually 
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change such that it no longer squares with one of the specific subtypes: this 
appears to be more common with the catatonic and hebephrenic subtypes than 
with paranoid or simple schizophrenia. 
 Before leaving this discussion of subtypes, it is appropriate to briefly 
discuss another proposal for subdividing schizophrenia, which is said by some to 
have more predictive and heuristic value than the classical sub typing just 
exposed. 
Two subdivisions are proposed: ―good prognosis,‖ ―reactive,‖ or ―type I‖ 
schizophrenia, and ―poor prognosis,‖ ―process,‖ or ―type II‖  schizophrenia. 
The contrasting characteristics of these two subdivisions are outlined in Table 1. 
Table 1. type I and type II Schizophrenia. 
 
Although this ―good prognosis‖/―poor prognosis‖ scheme is useful, many patients 
do not fit neatly into type I or type II but rather evidence a mixture of features of 
both types. 
In most cases, schizophrenia exhibits one of two overall patterns. 
In one, the course of symptoms is waxing and waning, whereas in the other there 
is a more or less stable chronicity. 
 Type I Type II 
Premorbid personality Normal Poor adjustment 
Age of onset Late, often adult years Early 
Mode of onset Acute Gradual and insidious 
Symptoms associated with 
onset 
Confusion and 
depression 
Few 
Kind of symptoms Positive Negative 
Ventriculomegaly on CT 
scan 
Absent Present 
Course More favourable Unfavourable 
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The waxing and waning course is marked by exacerbations and partial remissions. 
The pattern of these changes is often quite irregular, as are the durations of the 
exacerbations and partial remissions, ranging from weeks, to months, or even 
years. 
Some patients, during episodes of partial remission of the ―positive‖ symptoms, 
may develop a sustained and pervasive depressed mood accompanied by typical 
vegetative symptoms. This condition, often referred to as a ―post psychotic 
depression‖, increases the risk of suicide. Importantly, such a post psychotic 
depression should not be confused with the frequent, transient, and isolated 
depressive symptoms seen during an exacerbation of the other symptoms of the 
illness. At times, exacerbations may be precipitated by life stresses; however, at 
other times they simply happen. Among the stresses that can precipitate 
exacerbations, living in a family with high ―expressed emotion‖ is important. 
Such family members tend to be intrusive, critical, and over-involved, and 
patients exposed to such an onslaught, even when provided with optimum medical 
treatment, are likely to relapse. Some patients experience this fluctuating course 
for their entire lives; in many others, however, after 5 to 20 years, this pattern 
gives way to one of stable chronicity. The stable chronicity seen in some patients 
may appear in some cases after the initial onslaught of symptoms seen at the onset 
of the disease has dampened, and in others, as for example those with simple 
schizophrenia, it may be apparent from the onset itself. Over long periods of time, 
patients with this course may show very slow progression until the disease 
eventually ―burns out‖ leaving them in a deteriorated state. 
The classical subtype diagnosis may allow for some prediction as to course. Those 
with paranoid or catatonic schizophrenia tend to pursue a fluctuating course, and 
of the two the eventual outcome appears to be worse for the catatonic subtype. 
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The hebephrenic and simple subtypes tend to pursue either a stable or 
progressively deteriorating chronicity, and of the two the simple subtype seems to 
often undergo the greatest deterioration. 
 Before leaving this discussion of the course of the disease, it is appropriate 
to consider whether or not schizophrenia, in the natural course of events, and in 
the absence of pharmacological treatment, ever undergoes a full and complete 
remission. 
Certainly, far-reaching remissions have been documented; indeed, in many cases 
patients may appear at first glance to be recovered, and if one‘s definition of 
―recovery‖ or ―remission‖ is broad enough, as is the case in many published 
studies, one might say that a remission did occur. However, on closer inspection 
one may generally find lingering residual symptoms in these ―recovered‖ patients, 
such as fleeting hallucinations, odd thoughts, mannerisms or a certain poverty of 
thought. Thus, although ―social‖ recoveries in the absence of treatment, although 
rare, do occur, it is very unlikely that, in the natural course of the disease, there is 
ever a restitutio ad integrum.  
Most of times this disease lead to important complications. 
Academic and business failure are common; most patients are incapable of 
sustaining intimate relationships. About half attempt suicide, and about 10% 
succeed. Most suicides occur early in the course of the illness; depressive 
symptoms, as are seen in post psychotic depression, male sex and unemployment 
increase the risk.  
A not uncommon, but often overlooked, complication is hyponatremia. Some 
patients become ―compulsive water drinkers‖; however, the hyponatremia appears 
not to be caused solely by excessive intake of water. The renal tubule cells appear 
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to be hypersensitive to ADH, leading to a urine osmolality that is less than 
maximally dilute relative to the degree of hyponatremia.  
There are no reliable markers for the later development of schizophrenia although 
research is being conducted into how well a combination of genetic risk plus non-
disabling psychosis-like experience predicts later diagnosis (Phillips et al.  2002). 
People who fulfill the 'ultra high-risk mental state' criteria, that include a family 
history of schizophrenia plus the presence of transient or self-limiting psychotic 
experiences, have a 20–40% chance of being diagnosed with the condition after 
one year.  
The use of psychological treatments and medication has been found effective in 
reducing the chances of people who fulfill the 'high-risk' criteria from developing 
full-blown schizophrenia. However, the treatment of people who may never 
develop schizophrenia is controversial, in light of the side-effects of antipsychotic 
medication; particularly with respect to the potentially disfiguring tardive 
dyskinesia and the rare but potentially lethal neuroleptic malignant syndrome.  
The most widely used form of preventative health care for schizophrenia takes the 
form of public education campaigns that provide information on risk factors and 
early symptoms, with the aim to improve detection and provide treatment earlier 
for those experiencing delays.  
The new clinical approach early intervention in psychosis is a secondary 
prevention strategy to prevent further episodes and prevent the long term 
disability associated with schizophrenia. 
Until the 1950s, the treatment and management of schizophrenia generally took 
place in large asylums where people remained confined for much of their lives.  
Although government policy initiated a programme of gradual closure of these 
large hospitals and the rehousing of the residents in the community, this process 
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was greatly assisted by the introduction of antipsychotic drugs, such as 
chlorpromazine, thioridazine and haloperidol. Antipsychotic medication would 
become the mainstay of treatment for the rest of the 20th century.  
Patients may also be seen in supportive psychotherapy, either on an individual 
basis or in a group, and in social skills training groups.  
A ―token economy‖ approach may be required for severely debilitated patients.  
Families may also be seen, not only for educational purposes, but also to enable 
them to lessen the kinds of family interactions that tend to be followed by relapse. 
Assistance may be required to enable the patient to secure housing and 
employment.  
 The effectiveness of schizophrenia treatment is often assessed using 
standardized methods, one of the most common being the Positive and Negative 
Syndrome Scale (PANSS) (Kay et al.  1987). Management of symptoms and 
improving function is thought to be more achievable than a cure.  
Nowadays, within both hospital and community settings, antipsychotic medicines 
remain the primary treatment for schizophrenia.  
In general, the term ―antipsychotics‖ refers to the class of drugs used to treat 
schizophrenia and other psychotic illness. The antipsychotic potency of most 
antipsychotics is directly proportional to their ability to block dopamine receptors 
in the brain, although the exact mechanism by which they exert their antipsychotic 
effect is probably more complicated than this. They vary greatly in their 
selectivity for dopamine receptors, many also having significant effects on 
acetylcholine, norepinephrine, histamine and serotonin pathways. Unfortunately, 
using this class of drugs, a wide range of side effects is to be expected. 
Of these the most common are:  
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 Extrapyramidal side effects: dystonic reactions (such as oculogyric, spasm 
and torcicollis), pseudoparkinsonism (tremor, bradykinesia and rigidity), 
akathisia (a subjectively unpleasant state of motor restlessness) and tardive 
dyskinesia. 
 Hyperprolactinaemia: it is an expected phenomenon since prolactin is 
under the inhibitory control of dopamine. Hyperprolactinaemia can lead to 
galactorrhoea, amenorrhoea, gynaecomastia, hypogonadism, sexual 
dysfunction and increased risk of osteoporosis (Dickson et al.  2000; 
Smith et al.  2002). Long-stay psychiatric female inpatients have been 
noted to have nine fold increase in the risk of breast cancer when 
compared to the normal population (Halbreich et al.  1996). Although 
other risk factors are undoubtedly important in this group of patients, 
prolonged hyperprolactinaemia is likely to be a contributing factor. A 
measurement of serum prolactin can be a useful indicator that the (older, 
first generation) antipsychotic drug is being taken and is reaching CNS 
dopamine receptors.  
 Reduced seizure threshold: grand mal seizures are a recognized side effect 
of antipsychotic therapy (the higher the dose, the greater the risk).  
 Postural hypotension: this side-effect is mediated through adrenergic 
alpha1-blockade, and so can usually be predicted for any drug with 
significant antagonist activity at this receptor.  
 Anticholinergic side-effects: dry mouth (which may contribute to dental 
decay, ill-fitting dentures) , blurred vision (which can contribute to fall in 
the elderly) and constipation (impaction can occur). Anticholinergic 
effects may also have a detrimental impact on cognitive functioning. 
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 Neuroleptic malignant syndrome (NMS): it is a potentially life-threatening 
complication of neuroleptic treatment, with the mortality rate estimated as 
being up to 20%. It may occur in as 0.5% of patients treated with first-
generation antipsychotics and is thought to be greatly under-diagnosed. 
The main symptoms of NMS are mild hyperthermia, fluctuating 
consciousness, muscular rigidity, autonomic instability and severe EPSEs 
(primarily rigidity). Serum CPK is always raised. The enormous load of 
muscle breakdown products can lead to severe renal damage. The 
syndrome is believed to be caused by the rapid blockade of hypothalamic 
and striatal dopamine receptors, leading to a ―resetting‖ of the 
thermoregulatory systems and severe skeletal muscle spasm, which 
contributes to a considerable heat load that cannot be dissipated.  
 Weight gain: people with schizophrenia, in comparison to the general 
population, are more likely to be overweight and have increased quantities 
of visceral fat (Meyer, 2001; Thakore et al.  2002). A substantial 
proportion of patients will gain 7% of their baseline body weight, which 
increases the risk of obesity-related morbidity (for example type 2 
diabetes, heart diseases and some type of cancers).  
Moreover some antipsychotic drugs are sedative, some are cardio-toxic and many 
are associated with idiosyncratic side-effects.  
Furthermore antipsychotic treatment is a risk factor for venous thromboembolism 
(Zornberg and Jick, 2000), and in elderly patients who have dementia for stroke 
(Gill et al.  2005).  
 The antipsychotics may be broadly divided into two groups, namely ―first 
generation,‖ or ―typical‖ drugs, and ―second generation,‖ or ―atypical‖ drugs.  
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Commonly used first generation antipsychotics include haloperidol, fluphenazine 
and chlorproamzine.  
There is an ever growing number of second generation drugs, which now includes 
clozapine, olanzapine, risperidone, quetiapine, ziprasidone and aripiprazole. The 
main advantage of these second-generation (‗atypical‘) antipsychotics (SGAs) 
appears to be that they have a lower liability for acute EPS and tardive dyskinesia. 
All the antipsychotics have a well-established evidence for efficacy in both the 
treatment of acute psychotic episodes and relapse prevention over time (Janicak, 
1993). 
However, despite this, considerable problems remain. 
 A significant proportion of service users have a poor response to conventional 
antipsychotic drugs and continue to show moderate to severe psychotic symptoms 
(both positive and negative). 
 Approximately one fifth to one third of patients with schizophrenia, in fact, 
derives little or no benefit from monotherapy with first-line antipsychotics 
(Conley and Kelly, 2001). In these treatment-refractory patients only one 
antipsychotic drug, clozapine, has a specific license for the treatment and it has 
been shown to be the treatment of choice (Kane et al.  1988a; Rosenheck et al.  
1997). 
 Clozapine is the archetypal antipsychotic. It has been around since the 
1960s and was withdrawn from use after an association with neutropenia 
(incidence 3%) and agranulocytosis (0.8%) was made. The pivotal study by Kane 
et al.(Kane et al.  1988b) in the late 1980s proved that clozapine was more 
effective than conventional antipsychotics, and it was reintroduced in the UK with 
compulsory haematological monitoring. Patients must have a full blood count 
performed weekly for the first 18 weeks (when the risk of 
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neutropenia/agranulocytosis is greatest), fortnightly until 52 weeks of treatment, 
and then monthly thereafter if haematologically stable (the incidence of 
agranulocytosis after one year is similar to that associated with the 
phenothiazines).  
Clozapine treatment reduces suicidality and the data are sufficient for specific 
labelling for this indication in the USA.  
The pharmacology of clozapine is unusual compared with other antipsychotics in 
that it only binds weakly to D1 and D2 receptors, while having an affinity for D4, 
5HT2, 5HT3, alpha1 and alpha2 adrenergic, and Ach M1 and H1 receptors. 
Which one/combination of any of these effects is responsible for the superior 
clinical profile of clozapine is a subject of extensive speculation, but as of yet, no 
firm conclusion.  
Clozapine also has a unique side-effect profile in that it has been associated with 
an extremely low incidence of EPSEs, and is thought not to cause/precipitate 
tardive dyskinesia. Moreover it does not raise prolactin levels and so is not 
associated with amenorrhoea.  
Nevertheless, approximately one third of treatment-refractory patients have 
persistent positive and negative symptoms despite clozapine monotherapy of 
adequate dosage and duration (Kane et al.  1988a; Rosenheck et al.  1997). In 
these patients, partially responsive to clozapine, augmentation with haloperidol or 
other antipsychotic drugs is one of the most frequently therapeutic options 
employed in clinical practice, although the background evidence is limited and 
contradicttory (Mouaffak et al.  2006; Paton et al.  2007).     
 Haloperidol is a very potent D2 blocker. It is the most widely prescribed 
drug in the group of butyrophenones. Barbui and colleagues, who systematically 
reviewed the available literature, included six placebo-controlled randomized 
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trials conducted in Western countries and 15 randomized trials conducted in 
China. The analysis revealed that, in comparison with addition of placebo, a 
second antipsychotic in addition to clozapine had modest to absent benefit (Barbui 
et al.  2009a). Additionally, a recent Cochrane review, which assessed the efficacy 
and tolerability of various clozapine combination strategies with antipsychotics in 
people with treatment-resistant schizophrenia, included three small randomized 
controlled trials that failed to show if any particular combination strategy was 
superior to the others (Cipriani et al.  2009a). 
 In recent years the availability of newer antipsychotic agents has increased 
the therapeutic options available in the management of clozapine partial 
responders and, among these newer agents, anecdotal reports have hypothesised a 
promising role for aripiprazole (Bowles and Levin, 2003; Marder et al.  2003).  
 Aripiprazole is a partial agonist at D2 receptors: full binding to D2 receptors 
reduces dopaminergic neuronal activity by about 30% (in the absence of 
dopamine, aripiprazole acts as a weak agonist). It is a potent antagonist at 5HT2a 
receptors and a partial agonist at 5HT1a receptors.  
In contrast to some of the other atypical antipsychotic agents, treatment with 
aripiprazole appears to be associated with minimal weight gain and minimal 
negative impact on metabolic parameters, a key aspect given that these adverse 
effects might occur during clozapine treatment (Cipriani et al.  2009d; Zou, 2004). 
In terms of positive symptoms, it has been suggested that the combination of 
clozapine and aripiprazole may lead to greater D2 receptor antagonism in 
mesolimbic pathways, and, additionally, may combine D2 and D4 antagonism 
(although the role of D4 receptors in antipsychotic efficacy is unclear). A 
challenging neurobiological rationale, with a highly synergistic antipsychotic 
potency without increasing the risk of adverse effects, has therefore been 
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proposed (Tapp et al.  2003). Henderson and colleagues, who conducted a six-
week open label trial to examine the effects of adjunctive aripiprazole in 
clozapine-treated subjects, showed that this combination had little or no effect in 
terms of psychotic symptoms, but was associated with a significant decrease in 
weight, body mass index, fasting total serum cholesterol and total triglycerides 
(Rendell et al.  2004). The only randomised placebo-controlled trial published so 
far, which included 62 clozapine-treated patients with refractory schizophrenia 
that were randomly assigned to double-blind combination treatment with 
aripiprazole or placebo, showed that aripiprazole did not lead to better control of 
symptom severity after 8 weeks of treatment, but benefits were observed in terms 
of negative symptoms (Kahn et al.  2008a). 
The only randomized, placebo-controlled trial conducted so far showed that, in 
comparison with augmentation with placebo, augmentation with aripiprazole was 
not associated with increased efficacy, but was associated with less adverse 
effects (Chang et al.  2008). 
Despite this paucity of positive results, the need to provide real-world suggestions 
for patients who do not have an optimal response to clozapine has prompted 
European and American treatment guidelines to recommend the concurrent 
prescription of a second antipsychotic in addition to clozapine in partially 
responsive patients, with no indication on which agent should be prescribed.  
In the randomized study presented in this thesis we therefore compared the 
relative effectiveness and tolerability of two clozapine combination strategies, 
namely clozapine and aripiprazole versus clozapine and haloperidol, a reference 
therapeutic option often employed under ordinary circumstances (Schumacher et 
al.  2003; Sernyak and Rosenheck, 2004). 
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3 METHODS 
 
Italian legislation on independent trials  
The Italian context of care is an ideal setting for independent randomised trials, 
given the implementation of a National Law (Decreto Ministeriale 17/12/04) that 
formally recognised the public health value of independent studies investigating 
the real-world effectiveness of already marketed pharmacological treatments. In 
2004 a Ministerial Decree was issued establishing rules to help implement 
pragmatic independent phase IV clinical trials. In essence, the Decree states that if 
the following set of conditions are met:  
 the study coordinating centre is independent of drug company support; 
 study results can be disseminated autonomously; 
 there is no personal financial interest in studying the drugs included in the 
trial; 
 the study drugs are licensed for the indication to be investigated; 
 then the National Health Service (NHS) materially supports the conduct of 
the trial in three ways: 
 drug costs are paid by the NHS; 
 there are no fees for submitting the study protocol to the local Ethics 
Committees; 
 continuing medical education credits are provided to local investigators. 
 
Considering that all above mentioned criteria are met by the Clozapine 
Haloperidol Aripiprazole Trial (CHAT), we took fully advantage of such 
legislation. In particular, drug costs (clozapine, aripiprazole and haloperidol) are 
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covered by the local health authorities, with two advantages: first, we had the 
possibility to carry out this study on a low budget, independently from drug 
companies and from other agencies; second, the drugs under study are prescribed 
in a way that is identical to that normally followed under real-word circumstances, 
with obvious advantages in terms of generalizability of study findings. 
 
Pragmatic versus explanatory design 
In recent years there has been a renewal of interest in pragmatic trials (also called 
practical, effectiveness or management trials), that is for studies that randomly 
assign real-world patients to licensed drugs with the aim of assessing their 
effectiveness (Schwartz and Lellouch, 1967a; Zwarenstein et al.  2008). While 
explanatory (or phase III) trials answer questions about whether an intervention 
can work under ideal conditions (efficacy), pragmatic (or phase IV) trials attempt 
to answer questions about whether an intervention will work in the real world. 
Explanatory trials are usually carried out by the pharmaceutical industry, while 
pragmatic trials are more often undertaken by groups of clinical researchers. 
Recent examples of pragmatic trials include the Clinical Antipsychotic Trials of 
Intervention Effectiveness (CATIE) (Lieberman et al.  2005) and the Cost Utility 
of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS) (Jones et 
al.  2006). 
 In Italy a seminal pragmatic study was an unblinded trial of intravenous 
streptokinase in early acute myocardial infarction that enrolled 11,806 patients in 
one hundred and seventy-six coronary care units (Gruppo Italiano per lo Studio 
della Streptochinasi nell'Infarto Miocardico (GISSI), 1986). The first report of this 
influential study was published in 1986 and in subsequent years there was an 
ongoing debate about the need to support such research. 
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In the field of mental health, however, only in very recent years criticism has 
focused on the current standard of the design of explanatory clinical trials. These 
studies typically enrol highly selected patients that are shortly followed and 
assessed with rating scales that are seldom used in clinical practice. In Italy this 
criticism has progressively led mental health professionals to constitute research 
networks with the aim of developing pragmatic studies. Such studies, ideally, are 
intended to answer real-world questions by enrolling everyday patients to be 
followed in the long-term using pragmatic outcome criteria commonly used in 
practice. Pragmatic measures include suicide attempts, treatment switching, 
hospitalization, school failure or truancy, job loss, or treatment discontinuation 
(Barbui and Cipriani, 2007; March et al.  2005; Schwartz and Lellouch, 1967b). 
CHAT is the first Italian example of this new attitude (Barbui C., 2007),and other 
studies will soon follow (Barbato A. et al.  2008). 
 
Design of the clozapine haloperidol aripiprazole trial (CHAT) 
The principal clinical question to be answered by CHAT was the relative 
effectiveness and tolerability of combination treatment with clozapine plus 
aripiprazole compared to combination treatment with clozapine plus haloperidol 
in patients with an incomplete response to treatment with clozapine over an 
appropriate period of time. 
CHAT is a prospective, multicentre, randomized, parallel-group, superiority trial 
that follows patients over a period of 12 months. Consecutive patients meeting the 
trial entry criteria were randomly assigned to combination with aripiprazole or 
haloperidol. Patients and clinicians were not blind to pharmacological treatments 
provided during the trial. Patients were assessed at baseline, at 3, 6 and 12 
months. 
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According to Italian legislation, ethics approval was received in each participating 
site. 
All phases of CHAT were recorded following the CONSORT statement (Moher et 
al.  2001).  
 
Pharmacological treatments 
In order to resemble everyday clinical practice, clinicians were allowed to 
prescribe the allocated pharmacological treatments (starting dose and dose 
changes) according to clinical status and circumstances. 
All dose changes were recorded. Following randomization, treatment was to be 
taken daily for 1 year unless some clear reason to stop develops. Before random 
allocation, patients were asked to discontinue any antipsychotic drugs other than 
clozapine. Long-acting antipsychotic drugs needed to be discontinued for at least 
two weeks before random allocation. All other concomitant medications were 
permitted. 
Routine care outside the trial continues as usual. During the study, participants 
were seen as often as clinically indicated with no extra visits required for the trial. 
 
Power analysis for sample size calculation  
At the time of development of the CHAT, only one antipsychotic trial employed 
discontinuation by any cause as the primary endpoint (Lieberman et al.  2005). On 
the basis of this trial, it was initially hypothesised a withdrawal proportion from 
allocated treatment within 3 months (primary study endpoint) of 25% in the group 
treated with clozapine plus haloperidol (control group). Moreover, it was 
hypothesised that the augmentation with aripiprazole (experimental group) would 
show a clinically significant advantage by producing a withdrawal proportion of 
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10%. A sample size of 194 patients (97 in each group) achieves 80% power to 
detect a difference of 15% between the two withdrawal proportions. The test 
statistic used is the two-sided Z test with pooled variance. The significance level 
of the test is targeted at 5%. Assuming that 10% of the participants could be lost 
within 3 months, or could not provide valid data at month 3, 216 (=194/0.90) 
patients should have been enrolled in order to obtain 194 evaluable subjects 
(Chow et al.  2003; Cipriani et al.  2009c). Therefore, the target total sample size 
for CHAT was 216 patients (108 in each group). 
Considering the possibility that the target sample size would not have been 
reached, we anticipated that the total sample size at the end of the enrolment 
period would have been around 100 patients. With such a total sample size, 
CHAT achieves 80% power to detect a difference of 20% between the two 
withdrawal proportions (25% in the group treated with clozapine plus haloperidol 
versus 5% in the group treated with clozapine plus aripiprazole). (fig.1) 
The sample size calculation was performed using PASS software (Hintze, 2004). 
 
 
Figure 1. Study potency 
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Random Allocation Procedure 
Patients were randomly assigned to one of the two treatment groups with an equal 
probability of assignment to each treatment (allocation ratio 1:1). 
A centralised randomization procedure was employed. The trial biostatistician 
prepared the sequence of treatments randomly permuted in blocks of constant 
size. The site investigators did not know the block size. 
The allocation was stratified by living condition (residential facility versus all the 
other living conditions) because in patients with resistant schizophrenia this hard 
variable may be considered a proxy of severity of illness. 
The randomization schedule was generated using STATA software 8 (StataCorp, 
College Station, TX, USA). 
Recruiting physicians were asked to contact an operator at
 
the World Health 
Organisation Collaborative Centre of the University of Verona. The operator had 
access to a computerised system
 
that provided, after information on the enrolled 
participant was entered, the patient‘s identification number (ID) and the allocated 
treatment. The operator had not access to the randomisation lists. 
This procedure of randomisation was developed to fully conceal treatment 
allocation (Altman and Schulz, 2001). 
 
Statistical consideration   
The statistical analysis was masked, i.e. the trial biostatistician was blinded to the 
treatment groups until the analysis had been completed. Moreover, the trial 
biostatistician was not involved in determining patients‘ eligibility, in 
administering the treatment, in measuring the outcomes or in entering data. 
Two data locks occurred during the study. The first one happened 3 months after 
the end of the enrolment period, when the information on the primary endpoint 
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and on the short-term secondary endpoints were available for all the participants. 
The second one happened at the end of the study (12 months after the end of the 
enrolment period), when information on the long-term secondary endpoints were 
available for all participants. Accordingly, two data analyses were performed on 
an intention-to-treat (ITT) basis. All randomised participants who received at least 
one dose of the investigational drugs will be were included in the ITT analysis.  
 
Statistical analysis 
All randomised participants who received at least one dose of the investigational 
drugs were included in the intention-to-treat (ITT) analysis of the primary 
outcome. The distribution of the socio-demographic, biometric, functional and 
clinical characteristics of the patients evaluated at baseline, and drugs utilization 
in the past and at randomization, were compared with the Pearson‘s chi-squared 
test, the Fisher‘s exact test, the Student‘s t-test and the Wilcoxon rank-sum test, as 
appropriate. No correction for multiple testing was performed.  
The BPRS total score (at baseline and at month 3) was computed as the sum of the 
scores obtained from the 24 items measuring positive/negative symptoms, 
depression/anxiety and disorganization. The LUNSERS total score (at baseline 
and at month 3) was computed as the sum of the scores obtained from the 39 and 
41 items for males and females, respectively, covering psychological, 
neurological, autonomic, hormonal and other miscellaneous side-effects, whereas 
the 10 ―red herring‖ items were not considered. In case of missing information, 
both the BPRS and LUNSERS total scores were computed multiplying the mean 
score obtained from the observed items by the total number of items (e.g. the 
LUNSERS total score for a male with k non-missing items is: [sum of the 
observed scores / k] * 39).  
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The proportion of patients withdrawing from the allocated treatment within three 
months (primary outcome) was compared between the two groups of treatment by 
the Person‘s chi-squared test, whereas the risk ratio was calculated using a 
Poisson regression model with a robust standard error (obtained by the Huber / 
White / sandwich estimator of the variance) and no offset (Zou, 2004). The 
change in severity of illness (measured by the BPRS total score) and the change in 
subjective tolerability of antipsychotic drugs (measured by the LUNSERS total 
score) from baseline to month 3 were compared between the two groups of 
treatment by the analysis of covariance with the value at baseline as a covariate 
and robust standard errors. 
A multivariable analysis was performed to compare the differential 
efficacy/tolerability of the two treatments adjusting for the potential confounding 
effect of the main prognostic factors measured at baseline (sex, age, living 
condition, BPRS and LUNSERS total scores), and to test the interaction between 
each prognostic factor and the allocated treatment. Poisson and linear regression 
models with robust standard errors (obtained by the Huber / White / sandwich 
estimator of the variance) and no offset were used (Zou, 2004). 
The statistical analysis was performed using STATA software 10 (StataCorp, 
College Station, TX, USA). 
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4 OUTCOMES 
Withdrawal from allocated treatment within three months was the primary 
outcome. This outcome was selected because stopping or changing antipsychotic 
combination treatment is a frequent occurrence and major problem in the 
treatment of patients with schizophrenia. 
Pragmatically, combination treatment was considered withdrawn if: 
 clozapine was continued and the allocated treatment stopped; 
 clozapine was stopped and the allocated treatment continued; 
 both clozapine and the allocated treatment were stopped; 
 other antipsychotic drugs were added on a regular basis to the allocated 
combination treatment. 
 Combination treatment was not considered withdrawn if: 
o other antipsychotic drugs were occasionally administered for 
emergency purposes (e.g., parenteral antipsychotic drug 
administration during Accident & Emergency admission); 
o antipsychotic treatment was temporarily stopped (for no more than 
two weeks in six months) for reasons not related to clinical status. 
 
Severity of illness was measured by means of the BPRS 24 (Ruggeri et al.  2005), 
and the perspective of patients exposed to antipsychotic agents by means of the 
LUNSERS (Morrison et al.  2000).  
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 5 RESULTS 
Characteristics and disposition of patients 
A total of 59 Italian centers took  part to the study. (Figure 2). 
Figure 3 depicts the enrollment, randomization and follow-up of study patients. 
Of 129 patients screened for inclusion, 106 were enrolled in the study and 
randomly assigned to treatment. With such a total sample size, the study had 85% 
power to detect a 20% difference in the proportion that discontinued the two 
assigned treatments (25% in the group treated with clozapine plus haloperidol 
versus 5% in the group treated with clozapine plus aripiprazole). All 106 patients 
constituted the ITT population for the primary outcome. No patients were lost to 
follow-up, although the BPRS and LUNSERS were not completed at month 3 for 
one patient, who was excluded from the analysis of these continuous outcomes. 
Table 2 shows the baseline demographic and clinical characteristics of the 
patients. The majority of patients were males, with a mean age of 40.3 and 41.5 
years in the aripiprazole and haloperidol groups, respectively; 35.8 and 34.0% 
were living in psychiatric residential facilities, and the median disease duration 
was 14 and 18 years in the aripiprazole and haloperidol groups, respectively. All 
patients had a diagnosis of schizophrenia at the MINI interview, and 26.4% in the 
aripiprazole group and 34.0% in the haloperidol group had a positive history for 
alcohol abuse. At baseline, patients had been receiving clozapine for 3.9 and 5.0 
years in the aripiprazole and haloperidol group, respectively. The great majority of 
patients had already received haloperidol in the past, while only a minority had 
received aripiprazole in the past.  
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      Figure 2. Recruiting Centers  
 
 
  
40 
 
 
Figure 3. Flow chart of the study CHAT. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
106 Randomly assigned 
129 Patients assessed for eligibility 
23 patients excluded 
Did not meet inclusion criteria = 17 
Refused to participate=4 
Other reason=2 
Other  
53 Clozapine + Haloperidole 53 Clozapine + Aripiprazole 
 
Primary outcome 
53 underwent BPRS analysis 
Secondary outcome 
52 underwent BPRS analysis 
52 underwent LUNSERS analysis 
3 months 
follow up 
Primary outcome 
53 underwent BPRS analysis 
Secondary outcome 
53 underwent BPRS analysis 
53 underwent LUNSERS analysis 
Primary outcome 
53 underwent BPRS analysis 
Secondary outcome 
52 underwent BPRS analysis 
52 underwent LUNSERS analysis 
12 months 
follow up 
Primary outcome 
53 underwent BPRS analysis 
Secondary outcome 
53 underwent BPRS analysis 
53 underwent LUNSERS analysis 
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Effectiveness and tolerability measures 
After three months, the analysis of the primary outcome revealed no difference in 
the proportion of patients who discontinued treatment between the aripiprazole 
and haloperidol groups (13.2 vs 15.1%, p = 0.780) (Table 3). 
Combination treatment was discontinued in 7 patients allocated to the aripiprazole 
group (4 patients discontinued aripiprazole and continued with clozapine 
monotherapy, 1 patients discontinued both aripiprazole and clozapine and started 
fluphenazine, and 2 patients interrupted aripiprazole for more than 15 days) and in 
8 patients allocated to the haloperidol group (5 patients discontinued haloperidol 
and continued with clozapine monotherapy, 1 patient discontinued haloperidol 
and added aripiprazole, 1 patient discontinued haloperidol and received clozapine 
combined with olanzapine and clotiapine, and 1 patient was given clotiapine in 
addition to clozapine and haloperidol). 
Drug use at month 3 according to the allocated treatment is presented in Table 4. 
The mean daily dose of clozapine was 421 and 395 mg in the aripiprazole and 
haloperidol group, respectively. Aripiprazole was administered at a mean daily 
dose of 11.8 mg, and haloperidol was administered at a mean daily dose of 2.8 
mg. There was no difference in the use of concomitant medications between the 
two groups. 
The 3-month change of the BPRS total score ( BPRS) was similar in the 
aripiprazole and haloperidol groups (-5.9 vs -4.4 points, p = 0.523), while the 3-
month decrease of the LUNSERS total score ( LUNSERS) was significantly 
higher in the aripiprazole group than in the haloperidol group (-7.4 vs -2.0 points, 
p = 0.006) after adjusting for the baseline value (Table 3). The differential 
LUNSERS in the aripiprazole and haloperidol groups was confirmed when the 
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14 subjects with at least one missing item in the LUNSERS total score at baseline 
and/or at month 3 were excluded from the analysis (-7.2 vs -1.8 points, p = 0.012).  
After twelve months, the analysis of the primary outcome revealed no difference 
in the proportion of patients who discontinued treatment between the aripiprazole 
and haloperidol groups (30.8 vs 38.0%, p = 0.442) (Table 4). The 12-month 
change of the BPRS total score ( BPRS) was similar in the aripiprazole and 
haloperidol groups (-7.0 vs -7.7 points, p = 0.801), while the 12-month decrease 
of the LUNSERS total score ( LUNSERS) was only slightly higher in the 
aripiprazole group than in the haloperidol group (-7.0 vs -2.3 points, p = 0.085) 
after adjusting for the baseline value (Table 5).  
 
Multivariable analysis 
The comparison of the efficacy/tolerability between aripiprazole and haloperidol 
adjusted for the prognostic factors measured at baseline provided the same results 
as those obtained in the main analysis (Table 6). The differential LUNSERS 
between the allocated treatments (beta regression coefficient ( ) = difference 
between the adjusted mean LUNSERS in the aripiprazole group and the adjusted 
mean LUNSERS in the haloperidol group = -5.4 points, 95% CI: -9.4 to -1.5) 
was confirmed when the 14 subjects with at least one missing item in the 
LUNSERS total score at baseline and/or at month 3 were excluded from the 
analysis (  = -5.5 points, 95% CI: -9.9 to -1.2). 
Female sex (risk ratio (RR) = 3.60, 95%CI: 1.44 to 8.98) and younger age (RR = 
0.72, 95%CI: 0.59 to 0.88, for a 5-year increase of age at baseline) were both 
associated with a higher risk of treatment withdrawal. Additionally, a higher 
LUNSERS total score at baseline was positively associated with the primary 
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outcome (RR = 1.11, 95% CI: 1.00 to 1.23, for a 5-point increase of the score at 
baseline), even if this relationship did not reach the statistical significance (p = 
0.051).  
Higher values of the BPRS total score at baseline were significantly associated 
with a greater 3-month decrease of the BPRS total score (  = BPRS for a 5-point 
increase of the score at baseline = -1.1 points, 95% CI: -1.9 to -0.4).  
The negative association between the BPRS total score at baseline and BPRS 
was confirmed when the 12 subjects with at least one missing item in the BPRS 
total score at baseline and/or at month 3 were excluded from the analysis (  = -1.4 
points, 95% CI: -2.1 to -0.7). 
A statistically significant interaction (p = 0.011) was found between the allocated 
treatments, the LUNSERS total score at baseline and LUNSERS. In particular, a 
3-month decrease of the LUNSERS total score was found only among the patients 
in the aripiprazole group (  = LUNSERS for a 5-point increase of the score at 
baseline = -2.3 points, 95% CI: -3.1 to -1.4).  
The negative association between the LUNSERS total score at baseline and 
LUNSERS in the aripiprazole group was confirmed when the 14 subjects with at 
least one missing item in the LUNSERS total score at baseline and/or at month 3 
were excluded from the analysis (  = -2.4 points, 95% CI: -3.3 to -1.5). 
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6 DISCUSSION 
In the present randomized trial two clozapine combination strategies were 
compared in a representative sample of patients with treatment-resistant 
schizophrenia. In terms of treatment discontinuation and psychotic symptoms, 
clozapine combined with aripiprazole provided no additional benefit in 
comparison with clozapine combined with haloperidol. 
By contrast, in terms of tolerability, the addition of aripiprazole was associated 
with better patient perception of adverse effects.  
The background logic that guided the development of the present study was based 
on the need to provide real-world suggestions for patients who do not have an 
optimal response to clozapine and for whom clinicians feel the pressing need to 
add a second antipsychotic drug. 
 We made the choice of comparing two active clozapine combination 
strategies, without a placebo arm, as we reasoned that clinicians would have been 
reluctant to accept the possibility of allocating such difficult-to-treat-patients to 
placebo. The choice of haloperidol was determined
 
by prevailing clinical practice, 
and we designed the trial so that it would not interfere
 
with the routine care of 
participants: eligibility criteria
 
were simple, doses of the experimental drugs and 
concomitant medications were at the
 
discretion of the attending doctor, and data 
collection was minimised. Besides, the primary outcome was treatment 
discontinuation, a measure that integrates patients‘ and clinicians‘ judgments of 
efficacy, safety, and tolerability into a global measure of effectiveness that reflects 
their evaluation of therapeutic benefits in relation to undesirable effects 
(Lieberman et al.  2005). 
Likely, the open-label design employed in this trial has increased its external 
validity and generalizability (Cipriani et al.  2009d; Rendell et al.  2004). 
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Lack of improvement with the addition of aripiprazole compared to the addition 
of haloperidol is in line with the similarly negative studies of previous studies of 
augmentation of clozapine with various antipsychotics (Barbui et al.  2009b; 
Cipriani et al.  2009b). 
 The only randomized comparison that involved aripiprazole, carried out by 
Chang and colleagues, included 62 patients assigned to aripiprazole or placebo 
(Chang et al.  2008). After 8 weeks of double-blind treatment, aripiprazole 
augmentation of clozapine did not lead to a significant improvement of total 
symptom severity, but a favorable change in some adverse effects, including 
prolactin and triglyceride levels, was observed. 
In the present study we described adverse effects employing the patient viewpoint 
and, consistently with Chang and colleagues, it was found that the addition of 
aripiprazole was associated with a better perception of adverse effects. 
Observational case series of patients exposed to clozapine plus aripiprazole 
similarly suggested improvements in adverse effects, possibly mediated by a 
decrease in clozapine dose when compared with aripiprazole (Mule et al.  2008). 
In the present study, a negligible decrease in clozapine dosages was observed at 
follow-up in the aripiprazole group, while aripiprazole dose was similar to that 
recorded in the Chang and colleagues study (Chang et al.  2008). It is therefore 
possible the better perception of aripiprazole might be related to how this 
antipsychotic compares with haloperidol and not to the dose regimen of clozapine. 
 At the time that CHAT was designed, the CATIE trial was the only 
randomized study that employed treatment withdrawal as primary outcome 
measure. Subsequently, the results of the EUFEST study were published (Kahn et 
al.  2008b).  
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The EUFEST study was an open randomized controlled trial of haloperidol versus 
second-generation antipsychotic drugs in patients with schizophrenia aged 18-40 
years. In this study the primary outcome measure was all-cause treatment 
discontinuation. In contrast with the CATIE trial, and similarly to the CHAT, the 
EUFEST study employed treatment discontinuation as primary outcome with an 
open study design, in which patients knew which medication they were taking. In 
the EUFEST study a compelling discrepancy was found between treatment 
discontinuation, that was in favor of second-generation antipsychotics, and 
symptom scores measured using a rating scale administered under blind 
conditions, that found no differences between competitive treatments (Kahn et al.  
2008b). The authors hypothesized that expectations of psychiatrists could have led 
to haloperidol being discontinued more often, thus casting doubts on the use of 
treatment discontinuation under open conditions. We note that in the CHAT study 
no discrepancy between the primary outcome measure, recorded under open 
conditions, and symptom scores, recorded by blind staff, was observed. We 
therefore believe that the pragmatic design of the present study, including lack of 
blindness, should not have hampered the analysis of the main outcomes, 
considering that the design was based on a comparison of two active 
interventions, and doctors used to have no a priori expectations of which 
intervention would be better. 
Another issue is whether the open design of CHAT affected the ratings at the 
LUNSERS, considering that this scale was self-rated by patients who knew their 
drug assignment. 
We cannot rule out the possibility that expectations of patients led to haloperidol 
being systematically rated as more troublesome than aripiprazole, although we 
note that no association between LUNSERS ratings and antipsychotic drug 
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treatment (first versus second generation) was found in a recent multicentre study 
conducted in four European countries (Barbui et al.  2005). It is therefore 
reasonable to assume that patients had no a priori expectations of which 
intervention would be better tolerated. Additionally, if patients had had strong a 
priori expectations against haloperidol then they would not have consented to be 
randomly included in a study with 50% of possibilities to receive haloperidol. 
 The main limitation of this study is that we failed to reach the target sample 
size. 
Although CHAT is the largest randomized comparison so far carried out in a 
Western country in this difficult-to-treat population, the confidence interval 
around the risk ratio point estimate ranges from the possibility that aripiprazole is 
appreciably better than haloperidol to the possibility that haloperidol is 
appreciably better than aripiprazole. 
Another potential weakness is that lack of blindness leaves the possibility of 
performance bias, that is investigators and participants might have behaved 
systematically differently dependent on the allocated treatment. Although we 
cannot completely rule out this possibility, we note that the involvement of many 
recruiting sites and many investigators should have diluted this possibility, 
making very unlikely that in different sites different investigators systematically 
behaved differently dependent on the allocated treatment. The observed lack of 
difference in the primary outcome seems to provide further indirect evidence 
against the possibility of performance bias.  
The multivariable analysis further reinforced the relationship between allocated 
treatment and perception of adverse effects: having adjusted for possible 
confounders, clozapine plus aripiprazole was associated with a higher 3-month 
decrease of the LUNSERS score as compared to clozapine plus haloperidol. 
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Additionally, female sex, young age, and negative perception of adverse effects 
were independent prognostic factors of the risk of withdrawal within three 
months. This is in line with epidemiological data suggesting that, in real world 
settings, age, gender and adverse effects are associated with treatment adherence, 
including adherence to antipsychotic drug treatment (Nose et al.  2003). Young 
age is associated with lower illness insight, and therefore it is possible that young 
people may be more reluctant to adhere to antipsychotic drug treatment, especially 
when two agents are prescribed concurrently. Moreover, women perceive 
antipsychotic drugs as less tolerable than men (Barbui et al.  2005), and therefore 
the relationship between female gender and treatment discontinuation might be 
mediated by poor tolerability.  
 In conclusion, the results of this study indicate that augmentation of 
clozapine with aripiprazole offers no benefit with regard to treatment withdrawal 
and overall symptoms in schizophrenia as compared with augmentation with 
haloperidol. However, the favorable advantage in the perception of adverse effects 
with aripiprazole treatment is encouraging. This finding needs to be replicated by 
additional randomized and observational studies that, ideally, should include a 
formal cost-effectiveness analysis that takes into consideration drug acquisition 
costs.  
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Table 2. Baseline characteristics of the patients according to the allocated treatment. 
 CLOZAPINE and 
HALOPERIDOL 
CLOZAPINE and 
ARIPIPRAZOLE 
 
 
n % / mean / median n % / mean / median p-value* 
Females (%) 53 32.1 53 37.7 0.541 
Age (years), mean (sd) 53 41.5 (9.4) 53 40.3 (10.3) 0.549 
High school diploma or academic degree (%) 53 35.8 51 41.2 0.577 
Occupational status (%) 
    employed / sheltered employed, house-person, 
student 
    unemployed 
    retired  
51 
 
33.3 
17.7 
49.0 
52 
 
28.8 
21.2 
50.0 
0.846 
Living in residential facility in the past six months (%) 53 34.0 53 35.8 0.839 
Length of stay in residential facility
†
 (years), median 
(IQR) 
15 2.7 (1.3-3.9) 14 3.2 (1.2-6.5) 0.513 
Living status (%) 
    alone 
    with relatives 
    with other patients 
    other  
52 
 
7.7 
53.9 
28.8 
9.6 
52 
 
9.6 
53.9 
36.5 
0.0 
0.138 
Diagnosis of schizophrenia (MINI criteria) (%) 53 100.0 53 100.0 - 
Disease duration (years), median (IQR) 52 18 (12-24) 52 14 (8-20) 0.076 
Number of hospital admissions during lifetime, 
median (IQR) 
53 5 (1-10) 53 3 (1-8) 0.428 
BPRS total score, median (IQR) 53 60 (52-79) 53 60 (52-71) 0.395 
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 CLOZAPINE and 
HALOPERIDOL 
CLOZAPINE and 
ARIPIPRAZOLE 
 
 n % / mean / median n % / mean / median p-value* 
Systolic blood pressure (mmHg), mean (sd) 48 124.7 (12.4) 49 122.3 (13.6) 0.361 
Diastolic blood pressure (mmHg), mean (sd) 48 81.4 (8.7) 49 77.8 (8.7) 0.041 
Body Mass Index (kg/m
2
), median (IQR) 48 26.8 (24.7-31.2) 45 25.9 (24.7-28.7) 0.389 
Electrocardiographic anomalies (%) 45 20.0 46 8.7 0.123 
Electroencephalographic anomalies (%) 42 11.9 40 7.5 0.713 
Mental retardation (%) 
    absent 
    mild 
    moderate / severe 
53 
 
94.3 
5.7 
0.0 
53 
 
94.3 
5.7 
0.0 
1.000 
Cognitive degradation (%) 
    absent 
    mild 
    moderate 
    severe 
53 
 
94.3 
3.8 
1.9 
0.0 
53 
 
85.0 
7.5 
7.5 
0.0 
0.318 
Current alcohol abuse  (%) 53 0.0 52 0.0 - 
History of alcohol abuse  (%) 53 34.0 53 26.4 0.397 
History of self-harm behaviour (%) 53 18.9 52 11.5 0.296 
History of suicidal attempts (%) 53 20.8 51 11.8 0.215 
History of epilepsy (%) 51 7.8 53 3.8 0.432 
History of tardive dyskinesia (%) 53 7.5 52 5.8 1.000 
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 CLOZAPINE and 
HALOPERIDOL 
CLOZAPINE and 
ARIPIPRAZOLE 
 
 n % / mean / median n % / mean / median p-value* 
Past use of clozapine  
    length (years), median (IQR) 
    max dose (mg/die), mean (sd) 
 
53 
52 
 
5.0 (1.8-8.6) 
483 (158) 
 
52 
51 
 
3.9 (1.7-8.2) 
452 (118) 
 
0.524 
0.266 
Past use of haloperidol (%) 53 88.7 52 76.9 0.110 
Past use of aripiprazole (%) 53 3.8 52 9.6 0.270 
Past use of other antipsychotics (%) 53 94.3 52 92.3 0.716 
Past use of new antipsychotics
‡
 (%) 53 73.6 52 76.9 0.692 
Past use of depot antipsychotics (%) 53 15.1 53 13.2 0.780 
Dose of clozapine (mg/die) at baseline, mean (sd) 53 413 (157) 53 418 (141) 0.871 
Dose of haloperidol (mg/die) at baseline, mean (sd) 53 2.1 (1.3) - - - 
Dose of aripiprazole (mg/die) at baseline, mean (sd) - - 53 8.7 (3.9) - 
Use of other drugs at baseline (%) 
    antidepressants 
    benzodiazepines 
    mood stabilizers 
53 
67.9 
18.9 
62.3 
18.9 
53 
77.4 
24.5 
69.8 
9.4 
0.276 
 Use of anticholinergics at baseline (%) 53 0.0 53 1.9 1.000 
LUNSERS total score, median (IQR) 53 22 (16-32) 53 23 (16-32) 0.791 
sd: standard deviation, IQR: interquartile range  
* obtained by the Pearson‘s chi-squared test, the Fisher‘s exact test, the Student‘s t-test or the Wilcoxon rank-sum test 
†
 only for the 18 and 19 patients allocated to clozapine and haloperidol, and to clozapine and aripiprazole, respectively, who reported a 
stay in a residential facility in the past 6 months 
‡
 risperdal, clozapine, olanzapine, quetiapine, zotepine, ziprasidone, aripiprazole or amilsulpiride 
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Table 3. Withdrawal from the allocated treatment within three months (primary outcome), change in the BPRS total score 
(∆BPRS) and change in the LUNSERS total score (∆LUNSERS) from baseline to month 3. Comparison between the 
allocated treatments (reference group: clozapine and haloperidol). 
 CLOZAPINE and 
HALOPERIDOL 
CLOZAPINE and 
ARIPIPRAZOLE 
p-value 
Withdrawal from the allocated treatment 
number of patients (number of events) 
cumulative incidence (SE) [95%CI]* 
risk ratio (SE) [95%CI]
‡
 
 
 
53 (8) 
15.1% (4.9%) [6.7%, 27.6%] 
1.00 
 
 
53 (7) 
13.2% (4.7%) [5.5%, 25.3%] 
0.87 (0.42) [0.34, 2.25] 
 
 
0.780
†
 
 
∆BPRS 
number of patients 
adjusted mean change
¶
 (SE) [95%CI] 
beta regression coefficient
§
 (SE) [95%CI] 
 
52 
-4.4 (1.5) [-7.5, -1.4] 
0.00 
 
53 
-5.9 (1.7) [-9.4, -2.5] 
-1.5 (2.3) [-6.1, +3.1] 
 
 
0.523 
 
∆LUNSERS 
number of patients 
adjusted mean change
¶
 (SE) [95%CI] 
beta regression coefficient
§
 (SE) [95%CI] 
 
52 
-2.0 (1.4) [-4.8, +0.8] 
0.00 
 
53 
-7.4 (1.3) [-10.0, -4.8] 
-5.4 (1.9) [-9.2, -1.5] 
 
 
0.006 
 
SE: standard error, 95%CI: 95% confidence interval 
* binomial exact confidence interval 
†
 obtained by the Pearson‘s chi-squared test 
‡
 obtained by a Poisson regression model with a robust standard error and no offset 
¶
 mean ∆BPRS / ∆LUNSERS, adjusted for the baseline mean-centered value of the BPRS / LUNSERS total score by a linear regression 
model with robust standard errors 
§
 difference between the adjusted mean ∆BPRS / ∆LUNSERS among the patients allocated to clozapine and aripiprazole, and the 
adjusted mean ∆BPRS / ∆LUNSERS among the patients allocated to clozapine and haloperidol 
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Table 4. Drug use at month 3 according to the allocated treatment.  
 
CLOZAPINE and 
HALOPERIDOL 
CLOZAPINE and 
ARIPIPRAZOLE  
 
n % / mean n % / mean p-value* 
Dose of clozapine (mg/die) at month 3, mean 
(sd) 
53 395 (161) 52 421 (142) 0.376 
Dose of haloperidol (mg/die) at month 3, mean 
(sd) 
46 2.8 (1.7) - - - 
Dose of aripiprazole (mg/die) at month 3, mean 
(sd) 
1 15 (-) 48 11.8 (5.1) - 
Use of other drugs at month 3 (%) 
antidepressants 
benzodiazepines 
mood stabilizers 
53 
67.9 
24.5 
56.6 
17.0 
53 
69.8 
18.9 
62.3 
11.3 
0.834 
Use of anticholinergics at month 3 (%) 53 1.9 53 3.8 1.000 
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Table 5. Withdrawal from the allocated treatment within twelve months, change in the BPRS total score (∆BPRS) and change 
in the LUNSERS total score (∆LUNSERS) from baseline to month 12. Comparison between the allocated treatments 
(reference group: clozapine and haloperidol). 
 CLOZAPINE and 
HALOPERIDOL 
CLOZAPINE and 
ARIPIPRAZOLE 
p-value 
Withdrawal from the allocated treatment 
    number of patients (number of events)    
    cumulative incidence (SE) [95%CI]* 
    risk ratio (SE) [95%CI]
‡
 
 
52 (16) 
30.8% (6.4%) [18.7%, 45.1%] 
1.00 
 
50 (19) 
38.0% (6.9%) [24.7%, 52.8%] 
1.23 (0.34) [0.72, 2.12] 
 
 
0.442
†
 
 
∆BPRS 
    number of patients     
    adjusted mean change
¶
 (SE) [95%CI] 
    beta regression coefficient
§
 (SE) [95%CI] 
 
51 
-7.7 (1.6) [-10.9, -4.5] 
0.00 
 
50 
-7.0 (2.2) [-11.5, -2.5] 
+0.7 (2.8) [-4.8, +6.2] 
 
 
0.801 
 
∆LUNSERS 
    number of patients     
    adjusted mean change
¶
 (SE) [95%CI] 
    beta regression coefficient
§
 (SE) [95%CI] 
 
51 
-2.3 (2.0) [-6.4, +1.7] 
0.00 
 
50 
-7.0 (1.8) [-10.5, -3.5] 
-4.7 (2.7) [-10.0, +0.7] 
 
 
0.085 
 
SE: standard error, 95%CI: 95% confidence interval 
* binomial exact confidence interval 
†
 obtained by the Pearson‘s chi-squared test 
‡
 obtained by a Poisson regression model with a robust standard error and no offset 
¶
 mean ∆BPRS / ∆LUNSERS, adjusted for the baseline mean-centered value of the BPRS / LUNSERS total score by a linear regression 
model with robust standard errors 
§
 difference between the adjusted mean ∆BPRS / ∆LUNSERS among the patients allocated to clozapine and aripiprazole, and the 
adjusted mean ∆BPRS / ∆LUNSERS among the patients allocated to clozapine and haloperidol 
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Table 6. Withdrawal from the allocated treatment within three months, change in the BPRS total score (∆BPRS) and change 
in the LUNSERS total score (∆LUNSERS) from baseline to month 3. Mutually adjusted risk ratios† and beta regression 
coefficients
‡
 for the association between the allocated treatment, the main prognostic variables measured at baseline and the 
short-term outcomes. 
 
Withdrawal from the 
allocated treatment  
(n = 106) 
 
∆BPRS                                      
(n = 105) 
∆LUNSERS                                 
(n = 105) 
 
risk ratio [95%CI] 
 
beta regression coefficient [95%CI] 
Allocated treatment 
 (cloz. and aripiprazole vs cloz. 
and haloperidol) 
0.77 [0.26, 2.25] 
 
-1.5 [-6.1, +3.1] -5.4 [-9.4, -1.5] * 
Gender (female vs male) 3.60 [1.44, 8.98] * 
 
+3.3 [-1.6, +8.1] -1.7 [-6.4, +2.9] 
Age
¶
 (5-year increase)  0.72 [0.59, 0.88] * 
 
-0.1 [-1.4, +1.1] +0.4 [-0.7, +1.4] 
Living condition in the past six 
months 
(residential facility vs at home) 
2.10 [0.89, 4.98] 
 
+1.4 [-3.4, +6.3] -0.9 [-5.0, +3.2] 
BPRS total score
¶
  
(5-point increase) 
1.05 [0.93, 1.20] 
 
-1.1 [-1.9, -0.4] * -0.1 [-0.7, +0.5] 
LUNSERS total score
¶ 
(5-point increase) 
1.11 [1.00, 1.23] 
 
-0.6 [-1.5, +0.3] 
-0.5 [-1.5, +0.5]
§
 
-2.3 [-3.1, -1.4]
§ 
** 
Constant 
  
-6.1 [-9.8, -2.3] * -0.9 [-4.1, 2.2] 
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Modulo di consenso informato 
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Luogo e data ____________ 
Io sottoscritto/a _______________ nato a _________________ 
residente a _____________ in via __________________________ 
dichiaro 
di accettare la proposta di sottopormi alla sperimentazione clinica denominata 
CLOZAPINA E ARIPIPRAZOLO VERSO CLOZAPINA E ALOPERIDOLO NEL 
TRATTAMENTO DELLA SCHIZOFRENIA 
Sono stato/a adeguatamente informato/a circa gli scopi dello studio e le metodiche dello 
stesso, in particolare sono consapevole della necessità di osservare le indicazioni e le 
regole che mi sono state illustrate e che ho perfettamente compreso. 
Sono a conoscenza dei benefici che mi possono derivare dalla partecipazione allo 
studio, ma anche degli eventuali rischi e di tutti i disagi connessi. 
Mi è stato spiegato che dal nuovo trattamento ci si attendono risultati migliori o 
comunque vantaggi rispetto ai trattamenti oggi in uso; ad ogni modo mi è stato 
assicurato che non subirò, prevedibilmente, alcun aggravamento delle mie condizioni 
cliniche né vi sarà un ritardo nei tempi solitamente necessari, in casi analoghi, per la 
guarigione, per la stabilizzazione della patologia o per il controllo della sintomatologia. 
Sono consapevole che in qualsiasi momento potrò sospendere la sperimentazione ed 
esigere di essere curato/a con le terapie ordinarie per la patologia di cui soffro, senza 
obbligo da parte mia di motivare la decisione, a meno che la stessa non derivi dalla 
comparsa di disturbi o effetti indesiderati o non previsti, nel qual caso mi impegno sin 
da ora a comunicarne tempestivamente al medico sperimentatore natura ed entità. 
Dichiaro che il mio consenso è espressione di una libera decisione, non influenzata da 
promesse di denaro o di altri benefici, né da obblighi di gratitudine o di amicizia e/o 
parentela nei confronti del medico sperimentatore. 
Acconsento che le notizie riguardanti la sperimentazione, limitatamente a quelle che 
potrebbero rivelarsi utili ai fini della mia salute, vengano trasmesse al mio medico 
curante, dott. __________ 
Autorizzo sin d‘ora l‘utilizzo e la divulgazione, in forma anonima e per sole finalità 
scientifiche e amministrative e nell‘osservanza delle vigenti norme sulla tutela della 
riservatezza, dei risultati della sperimentazione, compresi i dati clinici che mi 
riguardano. 
 
Firma 
_______________________ 
Il Medico Sperimentatore 
_______________________ 
_______________________ 
(nome in stampatello) 
 
Testimone 
_______________________ 
_______________________ 
(nome in stampatello) 
 
Allegato: n._____ fogli contenenti notizie sugli scopi, metodi, benefici attesi e rischi, 
 connessi con la sperimentazione.  
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Scheda di follow up 
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Scheda di segnalazione di reazione avversa 
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Scheda di variazione terapia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
85 
 
 
  
86 
 
 
 
 
 
 
 
 
 
Appendice 6 
 
 
Lettera di approvazione dell’Agenzia Italiana del Farmaco 
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